Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TRAP Clear all
Completed Phase 1 Interventional

Intravitreal Aflibercept Injection for Radiation Retinopathy

NCT01579760
View directory record Official record
Conditions
Radiation Retinopathy, Macular Edema
Interventions
Aflibercept every 2 months, Aflibercept monthly
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Not applicable Interventional Results available

A Pilot Randomized Controlled Trial for Hand Osteoarthritis

NCT04784065
View directory record Official record
Conditions
Hand Osteoarthritis
Interventions
Hand orthosis
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

NCT00327444
View directory record Official record
Conditions
Ovarian Neoplasms, Ascites
Interventions
aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT00532155
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 20, 2026, 6:58 AM EDT
Completed No phase listed Observational

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

NCT00264082
View directory record Official record
Conditions
Breast Cancer
Interventions
Zometa(drug)
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 20, 2026, 6:58 AM EDT
Recruiting Phase 2 Interventional

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

NCT07202000
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Activin ligand-trap biological therapy, Placebo, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01258855
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
21
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 20, 2026, 6:58 AM EDT
Terminated Phase 1 Interventional

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03579472
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Bintrafusp Alfa, Eribulin Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 20, 2026, 6:58 AM EDT
Not listed No phase listed Observational

Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M

NCT04066933
View directory record Official record
Conditions
Complex Regional Pain Syndromes, Neuralgia, Thoracic Outlet Neurologic Syndrome
Interventions
A2M enriched plasma
Combination Product
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
23 Years to 77 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 6:58 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of a Disposable Flexible Bronchoscope, aScope IV

NCT02255838
View directory record Official record
Conditions
Respiratory Insufficiency, Pneumonia, Atelectasis
Interventions
Bronchoscope reusable (Storz 8402 2x), Bronchoscope disposable (aScope 4)
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Not applicable Interventional Results available

Stress, Emotion Regulation, and Alcohol in Women Veterans

NCT04393623
View directory record Official record
Conditions
Alcohol Use Disorder, Post Traumatic Stress Disorder
Interventions
Cognitive Reappraisal, Psychoeducation
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Leeds, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 6:58 AM EDT
Active, not recruiting Phase 2 Interventional

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

NCT04784416
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 6:58 AM EDT
Completed No phase listed Observational

Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media

NCT05133258
View directory record Official record
Conditions
Chronic Suppurative Otitis Media
Interventions
Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 20, 2026, 6:58 AM EDT
Terminated No phase listed Observational

Trevo Aspiration Proximal Flow Control Registry

NCT03199404
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
TRAP
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00450255
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
ziv-aflibercept, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

NCT00383370
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
VEGF Trap, VEGF Trap
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Fort Myers, Florida • Wichita, Kansas • Hagerstown, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

NCT00964795
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal Aflibercept Injection 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
115
States / cities
Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 20, 2026, 6:58 AM EDT
Recruiting Phase 4 Interventional

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

NCT06662994
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Drug
Lead sponsor
Retina Consultants of Orange County
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Not applicable Interventional

Safely Disposing of Surplus Prescription Opioids

NCT03855241
View directory record Official record
Conditions
Opioid Use
Interventions
Informational Sheet, DisposeRx Drug Disposal kit
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 20, 2026, 6:58 AM EDT
Terminated Phase 2 Interventional Results available

Aflibercept in Treating Patients With Myelodysplastic Syndromes

NCT00509249
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Interventions
ziv-aflibercept, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569
View directory record Official record
Conditions
Primary Immune Deficiency Disease
Interventions
Flebogamma 5% DIF
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 20, 2026, 6:58 AM EDT
Completed Phase 1 Interventional

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT03524170
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Bintrafusp Alfa, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 20, 2026, 6:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

NCT03451773
View directory record Official record
Conditions
Cancer of Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
Interventions
M7824, Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 20, 2026, 6:58 AM EDT